» Articles » PMID: 11383716

Effects of Ro 64-6198 in Nociceptin/orphanin FQ-sensitive Isolated Tissues

Overview
Specialty Pharmacology
Date 2001 Jun 1
PMID 11383716
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacological profile of the non-peptide OP4 receptor (ORL1, LC132) agonist, Ro 64-6198, was investigated, in three electrically stimulated nociceptin/orphanin FQ (NC)-sensitive preparations, namely the mouse and rat vas deferens and the guinea pig ileum. Ro 64-6198 mimicked the inhibitory effect of NC in the three preparations, while showing slow kinetics of action and a slowly reversible effect compared to the fast and immediately and completely reversible effect of the natural peptide. Ro 64-6198 displayed similar pEC50 and Emax values as NC in the mouse and rat vas deferens while it was 100-fold less potent but more efficacious (higher Emax) than NC in the guinea pig ileum. In the rat vas deferens the effects of Ro 64-6198 were antagonised by [Nphe1]NC(1-13)NH2 and J-113397 with pKB values (6.30 and 8.05, respectively) similar to those obtained against NC (6.20 and 7.77, respectively). Naloxone (1 microM) was inactive. In the guinea pig ileum a clear shift of the concentration response curve to Ro 64-6198 was obtained only using a cocktail of antagonists (naloxone + [Nphe1]NC(1-13)NH2 or naloxone + J-113397). In the mouse vas deferens the antagonists were inactive against Ro 64-6198 either when tested alone or in combination. Therefore, Ro 64-6198 behaved as a selective OP4 receptor agonist only in the rat tissue. These results suggest a physiological heterogeneity in OP4 receptors across tissues and species and may explain why, when tested in vivo, Ro 64-6198 mimics the potent anxiolytic effect of NC better in the rat than in the mouse.

Citing Articles

In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403.

Ferrari F, Malfacini D, Journigan B, Bird M, Trapella C, Guerrini R Pharmacol Res Perspect. 2017; 5(4).

PMID: 28805972 PMC: 5684865. DOI: 10.1002/prp2.333.


In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.

Ferrari F, Cerlesi M, Malfacini D, Asth L, Gavioli E, Journigan B Eur J Pharmacol. 2016; 793:1-13.

PMID: 27780725 PMC: 5555400. DOI: 10.1016/j.ejphar.2016.10.025.


Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Toll L, Bruchas M, Calo G, Cox B, Zaveri N Pharmacol Rev. 2016; 68(2):419-57.

PMID: 26956246 PMC: 4813427. DOI: 10.1124/pr.114.009209.


Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Zaveri N J Med Chem. 2016; 59(15):7011-28.

PMID: 26878436 PMC: 5001850. DOI: 10.1021/acs.jmedchem.5b01499.


In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives.

Rizzi A, Malfacini D, Cerlesi M, Ruzza C, Marzola E, Bird M Br J Pharmacol. 2014; 171(17):4138-53.

PMID: 24903280 PMC: 4243985. DOI: 10.1111/bph.12799.